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Introduction
In the United States, there are currently 5 million people 
affected by Alzheimer disease (AD). Alzheimer disease is a 
common form of dementia that severely affects a person’s cog-
nitive processes, most notably, significant memory loss. It is one 
of the top 10 causes of death that cannot be prevented, cured, or 
slowed.1 One of the largest obstacles in developing a treatment 
for AD is the inability to detect it in its early stages. Early treat-
ment of AD would play a fundamental role in preventing the 
memory loss associated with AD, helping to reduce the devas-
tating emotional and psychological effects of the disease. 
Alzheimer disease typically goes undetected for years, at which 
point significant anatomical and physiological changes have 
occurred in the brain structures—including atrophy and toxic 
plaque buildup, causing a steady decline in mental capabilities 
and memory processes before diagnosis.2 Current detection 
methods for AD are both expensive and ineffective in catching 
the disease in its early stages. Early detection of AD is limited 
when using structural magnetic resonance imaging (MRI), as 
the scans are largely used to identify atrophy in brain structures. 
The atrophy of the brain is a symptom of neurodegeneration 
accompanying AD; however, neurodegeneration is not limited 
to AD. Neurodegeneration also occurs in Parkinson disease and 
other forms of dementia. Furthermore, the identification of AD 
through an MRI tends to occur in later stages of the disease, 
making it an ineffective method for early detection of AD.3 In 
positron emission tomography scans, the person is subjected to 
radiation thereby limiting the number of images that can be 
collected in one period of time. Positron emission tomographic 
images do not tend to be used for high-resolution purposes or 
structural imaging.4 In addition, due to its high cost and use of 
radioactive isotopes, the technology is difficult to employ as an 
early-onset screening tool for every individual.5,6 The most 
promising biomarkers to identify AD are amyloid-E (AE) pro-
teins.7,8 These proteins reveal a significant structure that is key 
to understand the prognosis of AD. The AE proteins have been 
found in cerebrospinal fluid (CSF). When collected in CSF, it is 
possible to characterize the amount of amino acids in the AE 
and to determine the extent of plaque development. Although 
spinal taps give detailed information about the status of AD, it 
is an incredibly painful and invasive procedure. It would be near 
impossible to perform this method multiple times and is often 
only administered in the late stages of AD.9 Several studies 
involving the development of AE in patients with AD focus on 
the nervous system, ie, the brain or the spinal cord.3,4,8–11 The 
retina, as an extension of the nervous system, has proven to be a 
window into the pathologies of the brain. The development of 
AE in the brain is typically mirrored in the retina, especially in 
the primary visual cortex.12 This is a significant point of interest 
for the development of early detection methods for AD.10 
Because AE proteins have a fluorescent nature, they can be 
bound to imaging probes to allow for their visualization with 
the use of fluorescent imaging (FLI) technologies.
The FLI is an optical imaging technique that provides 
high-resolution images of the fluorescent nature of certain 
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molecules, ie, fluorophores. Fluorescence is characterized as 
the absorption and subsequent radiation of light by a speci-
men. Exogenous fluorophores, ie, imaging probes, bind to a 
specific molecule and allow for a clearer fluorescent image. 
Considering the development of AE on the retina, their small 
size in soluble form, and their ability to bind to fluorescent 
probes, obtaining fluorescent images of these proteins pro-
vides a promising method toward early detection of AD. 
Certainly, the clinical relevance of imaging AE for diagnostic 
purposes has been a topic of increasing interest. In their criti-
cal review of using AE sequelae in the eye as a diagnostic 
marker for AD, Shah et al13 indicate that observations of the 
lens and retina are the most promising avenues for this pur-
pose. The authors identify fluorescence as an encouraging 
modality for this identification but highlight the difficulty to 
distinguish endogenous fluorophores from biomarkers. This 
indicates the need for a more robust system capable of identi-
fying exogenous and endogenous fluorophores.
Biomarkers, such as CRANAD-2, have been previously 
used (oral or intravenous administration) due to their affinity 
to AE plaques.14–18 CRANAD-2 is derived from curcumin, a 
component of turmeric which has shown to have benefits in 
reducing AE aggregation, as well as other health benefits.15 The 
probe shows a significant enhancement of its fluorescent prop-
erties when in the presence of amyloid fibrils.15 Ran et  al16 
designed a CRANAD-2 probe specifically as an AE plaque 
marker for near-infrared (NIR) fluorescent imaging. The probe 
showed a specific affinity to the AE plaques, making it an ideal 
marker for fluorescent imaging.16 These biomarkers appear to 
activate in the presence of the plaques, showing measurable 
fluorescence.17 Imaging the probes through the retina allows 
changes to retinal tissue caused by AE plaque to be observed, 
thus decreasing the invasiveness of a diagnosis.18 In 2010, 
Karonyo-Hamaoui et al19 systemically administered curcumin 
to detect AE plaques in live AD-Tg mice and were then able to 
optically image retinal AE plaques in vivo, reporting that these 
plaques were not detected in non-Tg mice. In the same ground-
breaking article, in 2011, Karonyo-Hamaoui et al19 confirm the 
presence of retinal AE plaques in postmortem eyes of patients 
with AD as well as in patients suspected to have had early 
stages of AD. Further studies indicate that retinal plaques may 
associate with blood vessels in the superior quadrant and have 
an amyloid pathology similar to the brain.5,6,19–21 Moreover, the 
use of this biomarker extends beyond AE as Park et al22 further 
explored the use of CRANAD-2 in imaging tau fibrils. In 
addition, a variety of other probes with an affinity for AE have 
been detailed by Xu et al.23 These authors suggest the use of 
probes with a near NIR wavelength emission between 650 and 
900 nm to avoid background fluorescence from brain tissue.
In this study, we develop a fluorescent imaging system that 
can be used as a noninvasive detection method which could 
be administered frequently and easily in a clinical setting. The 
system is designed for viewing the development of AE plaque 
on the retina by imaging fluorescent probes with NIR emis-
sion spectra. Moreover, as this low-cost optical imaging sys-
tem is refined, it may have utility in other fields of medicine. 
Further research is needed to investigate its uses. For this rea-
son, we have designed the imaging setup and validation pro-
cess to enable the development of similar systems for other 
scientific areas.
Materials and Methodology
Experimental system setup
A Xiton Tunable Laser, ranging from 520 to 1024 nm, was used 
in our experiments as the excitation source. It allows adjustments 
of the excitation wavelength and the output power of the laser, to 
efficiently excite the fluorophores. The beam was spatially filtered 
by means of a standard iris (D12S; Thorlabs, Newton, NJ, USA). 
A 1-inch beam splitter (BS019; Thorlabs) was used for directing 
the light toward the sample and to split the beam power. The 
beam splitter directs the light onto the sample and allows the 
camera to image the sample in alignment with the beam path. 
Bandpass filters (FB 720-10 and FB 810-10; Thorlabs) were 
used as fluorescence emission filters for 710 and 810 nm, respec-
tively. A CMOS Camera with the pixel size of 5.5 Pm (GS3-U3-
41CNIR-C; Point Grey, Richmond, BC, Canada) was chosen 
due to its capabilities to detect AE fluorescence with a high quan-
tum efficiency at the wavelength range between 450 and 800 nm. 
A zooming, telocentric lens (VZM 450i; Edmund Optics Inc., 
Barrington, NJ, USA) with an adjustable zoom from ×1 to ×4 was 
used as the objective lens on the camera. The working resolution 
was determined as 5 Pm (measured by a 1951 USAF resolution 
target). Figure 1 depicts the experimental imaging setup.
This system has the potential to be modified for a range of 
applications and can be reconfigured on a fluorophore to fluoro-
phore basis. There are 2 modifications that have been developed 
and implemented for future experiments: the incorporation of a 
beam expander and a motorized emission filter wheel. The abil-
ity to magnify the beam is beneficial for imaging the entire ret-
ina. Emission filters allow a wavelength of the fluorophore to 
pass to the camera. However, in some cases, a sample may exhibit 
more than one fluoresce; since the imaging probe can have 2 
Figure 1. Experimental setup of the luorescent imaging: (a) camera, (b) 
imaging lens, (c) emission ilter, (d) 1-inch beam splitter, (e) iris, (f) sample 
holder, (g) beam expander, (h) mirrors, (i) laser pathway, and (j) tunable 
laser.
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different emission wavelengths—one when they are bound to 
their target molecule and another when they are not bound to 
the target molecule. Capturing an image of each instance is cru-
cial for understanding the sample. The motorized emission filter 
wheel is used for this purpose. The wheel is programmed with 
the Arduino to allow for the switches between emission filters.
Experimental system testing
To understand the fluorescent detection capabilities of our 
imaging system, a series of experiments were performed with 
Cyanine-5 (Cy5), a well-researched fluorophore. Cy5 is best 
excited at a wavelength of 649 nm and emits the finest fluores-
cent response at 675 nm. The full spectra of Cy5 are depicted in 
Figure 2A. To determine the feasibility of the imaging system 
in the diagnosis of AD, CRANAD-2 was also tested as an 
imaging probe. Through this experiment, it can be determined 
whether this system has the potential to detect AE in the ret-
ina. A previous study by Ran et al has determined the fluores-
cence spectra of CRANAD-2, both bound and unbound, to 
AE proteins. The spectra determined for unbound CRANAD-2 
are depicted in Figure 2B.16,24 In accordance with the excita-
tion wavelength of CRANAD-2, the laser was tuned to excite 
the sample using a 640 nm wavelength. A 710 nm filter would 
allow for the detection of CRANAD-2 bound to AE proteins.
Results and Discussion
Fluorescent detection
The first experiment was to prove that the fluorescent imag-
ing system can detect a fluorescent response from the Cy5 
dye. The use of Cy5 as a fluorophore allowed for a series of 
tests to understand the optical modulation of the system and 
to determine the best settings for the camera and laser. Two 
samples were imaged in this experiment: a microcentrifuge 
tube containing water was used as the control and a micro-
centrifuge tube containing Cy5 dye (12.5% concentration) 
was used as the variable. The results of the fluorescent exper-
iment with water are shown in Figure 3A and B. When the 
water was imaged without an emission filter, the object was 
seen clearly in the image. However, when imaged with the 
emission filter, no fluorescent response was detected. The 
results of the fluorescent experiment with Cy5 also provided 
the expected results. When the Cy5 was imaged without an 
emission filter, it was detected clearly by the camera as shown 
in Figure 3C. In addition, when the Cy5 was imaged with 
the 710 nm emission filter in place, its fluorescent response 
was detected, as shown in Figure 3D. To obtain quantitative 
values, a region of interest of 100 × 100 pixels was measured 
within each experimental image to determine the intensity 
value as shown in Figure 3E.
Figure 2. (A) Spectra of Cy5 for luorescence emission and excitation. Peak wavelength of excitation is at 649 nm, and the peak emission is at 675 nm. 
(B) Spectra of CRANAD-2 for luorescence emission and excitation. Peak wavelength of excitation is at 649 nm, and the peak emission is at 525 nm.16,24
Figure 3. Images of water illuminated with O-excitation of 649 nm: (A) without emission ilter and (B) with 710 nm emission ilter. Images of Cy5 illuminated 
with O-excitation of 649 nm: (C) without emission ilter and (D) with emission 710 nm ilter. (E) Averaged intensity of the pixels in the ROI indicated by the 
boxes in (A).
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This experiment demonstrates the fluorescent detection 
capabilities of our imaging system.
Optimizing laser optical power
Illuminating the fluorescent sample with the correct excitation 
wavelength is not the only necessary consideration when using 
an excitation source. The power of the source also needs to be 
optimized to have sufficient absorption. For this experiment, a 
sample of Cy5 was illuminated at 649 nm to match its peak 
excitation wavelength. The power of the laser was incrementally 
increased 10 times from 5 to 50 mW. Figure 4 shows the results 
of the fluorescent imaging of Cy5 target at different optical 
excitation powers. The results were as expected: the increase in 
optical power increased the fluorescent signal. To obtain quan-
titative values, an area of 100 × 100 pixels was measured within 
each experimental image to determine the intensity value.
Fluorescent response: agar phantom with Cy5 
injected
To determine the capability of the system for imaging the fluo-
rescent response, an experiment was conducted on an agar phan-
tom injected with Cy5. The use of agar as a medium for this 
experiment allows for both convenience and control over the 
imaging of the fluorescent material. A 3% agar phantom was 
created using standard laboratory techniques. Agar and distilled 
water were mixed and heated to a boil with constant stirring to 
ensure full incorporation of the powder. The heated mixture was 
poured into small molds to allow it to cool and solidify. The Cy5 
(with 5% concentration) was injected into areas as large as 
4 × 4 mm2 and into areas as small as 900 × 900 Pm2 (see Figure 5). 
A Petri dish containing this medium was held upright to allow 
for the imaging of the agar phantom with Cy5 injected.
However, the Cy5 in the phantom produced a fluorescent 
response; a noticeable difference between the variations of the 
Cy5 c concentrations was not clearly observed.
Fluorescent response: agar phantom with 
CRANAD-2 particles
Two samples were made for this experiment: a blank agar 
phantom and an agar phantom with CRANAD-2 particles in 
it. Figure 6A and B depicts the samples used in this experi-
ment. The fluorescent images of the samples are given in Figure 
6C and D. To obtain quantitative values, an area of 100 × 100 
pixels was considered within each experimental image to deter-
mine the intensity value. The excitation and emission wave-
lengths were 649 and 710 nm, respectively.
These results in Figure 6 demonstrated that CRANAD-2 could 
produce a signal; however, the fluorescent signal of the CRANAD-2 
was weak. The weak signal of CRANAD-2 is not entirely unex-
pected, as there was no binding agent for the dye to bond with. As 
detailed by Ran et al,24 when CRANAD-2 is imaged without being 
bound to an AE, it has a lower fluorescent signal strength.
Summary and Future Work
With an intention to develop a system that can identify AD at 
an early stage, we designed a fluorescent imaging system to 
image AE proteins. The resolution of the imaging system was 
sufficient to image microstructures as small as 5 Pm. The per-
formance of the system was tested using several phantoms. 
Different laser optical powers were tested. Two dyes were tested 
including Cy5 and CRANAD-2. CRANAD-2 was the pri-
mary contrast agent chosen for its use in diagnosing AD. Cy5 
was selected for the similarity in excitation-emission spectra to 
CRANAD-2 and for its strong fluorescent response which 
helped to validate our design. The experiment used an agar 
phantom injected with Cy5 dye at different concentrations and 
an agar phantom containing CRANAD-2 particles. We dem-
onstrated that the system will be capable of detecting the fluo-
rescent phenomenon of an AE protein as we could image 
CRANAD-2. The system is capable of being used for a wide 
range of applications and can be modified on a fluorophore to 
fluorophore basis. In future testing, phantom imaging of AE 
mixed with the CRANAD-2 will be performed to measure the 
ratio of bound to unbound CRANAD-2 particles and the type 
of fluorescent signal exhibited. In addition, future experiments 
Figure 4. (A) Fluorescent imaging of Cy5 target at different optical 
excitation powers with a 710 nm emission ilter. Colorbar depicts 
luorescent intensity (a.u.). (B) Quantitative intensity of images.
Figure 5. Agar phantom with Cy5 dye–injected areas. (A) Agar phantom 
with Cy5-injected areas. The square depicts the ield of view of our 
imaging. (B) Florescent image of the phantom.
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for in vivo retina imaging will be performed to determine 
whether CRANAD-2 and AE can be seen in an AD model.
This research provides validation for a simplified imaging 
system for the detection of AE proteins using fluorescence 
imaging techniques. In addition, the development of a func-
tioning imaging system with the capabilities of probe to probe 
variation is presented. Acknowledgements of the limitations of 
this study include those that result from the experimental 
design. The exploration of similar and alternative biomarkers 
for AE is warranted to determine the most feasible options for 
diagnosis using fluorescent imaging. Optimization of the imag-
ing system will increase the robustness of its capabilities. Laser 
safety will be provided by an optimum mechanical design of the 
device housing in which a beam dump is well-integrated.
Future work based on this design would involve in vivo imaging 
to validate its diagnostic potential. This could involve using such a 
system in conjunction with optical coherence tomography (OCT) 
to enhance its diagnostic capability.25,26 This combined system 
would allow for a noninvasive means to potentially diagnose AD 
with higher confidence, early in the disease’s progression. The fluo-
rescence imaging system and components would be modified and 
compacted to create a system with which a patient could simply 
peer into an opening to image their retina. Such a machine would 
be designed and used in a manner similar to the OCT machines 
currently being used in ophthalmology. Once developed, this sys-
tem could easily be implemented into an optometry practice to 
improve diagnostic procedures and outpatient services.
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